Credit: Getty Images. Olutasidenib is a small-molecule inhibitor of mutated IDH1. The Food and Drug Administration (FDA) has approved Rezlidhia™ (olutasidenib) for the treatment of adult patients with ...

VORANIGO (R) was approved by Health Canada in August 2024 for the treatment of Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation in adults and pediatric patients aged ...

Brain cancer is difficult to treat when it starts growing, and a prevalent type, known as a glioma, has a poor five-year survival rate. In a new study, researchers report on a new surgical platform ...

Agios Pharma’s Tibsovo gets US FDA nod to treat relapsed/refractory acute myeloid leukemia: Cambridge Tuesday, July 24, 2018, 17:00 Hrs [IST] Agios Pharmaceuticals, Inc, a leade ...

The US Food and Drug Administration (FDA) has approved vorasidenib (Voranigo, Servier) for the treatment of certain isocitrate dehydrogenase (IDH)–mutant diffuse gliomas, marking the first approval of ...

Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with Grade 2 gliomas with IDH1 or IDH2 mutations. Based on evidence from the INDIGO clinical trial, a global ...

A research team in Japan has developed an innovative system that can accurately detect genetic mutations in the brain tumor within just 25 minutes. Genetic mutations are crucial markers for diagnosis ...

Credit: Getty Images. Rezlidhia is a small molecule inhibitor of mutated IDH1. Rezlidhia ™ (olutasidenib) is now available for the treatment of adults with relapsed or refractory acute myeloid ...